A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

被引：14
|
作者：
Kulasekararaj, Austin [1 ,2 ]
Risitano, Antonio M. [3 ]
Maciejewski, Jaroslaw P. [4 ]
Notaro, Rosario [5 ,6 ]
Browett, Peter [7 ]
Lee, Jong-Wook [8 ]
Huang, Mingjun [9 ]
Geffner, Michael [10 ]
Brodsky, Robert A. [11 ]
机构：
[1] Kings Coll Hosp London, Dept Haematol, London, England
[2] Kings Collge London, London, England
[3] Univ Naples Federico II, Naples, Italy
[4] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA
[5] Azienda Osped Univ Careggi, Florence, Italy
[6] Inst Studio Prevenz & Rete Oncol, Florence, Italy
[7] Univ Auckland, Dept Mol Med & Pathol, Sch Med, Auckland, New Zealand
[8] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea
[9] Achillion Pharmaceut Inc, New Haven, CT USA
[10] Achillion Pharmaceut Inc, Blue Bell, PA USA
[11] Johns Hopkins Univ, Dept Med, Div Hematol, Baltimore, MD USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3514
引用
收藏
页数：5
相关论文
共 50 条
  • [1] A phase 2 open-label study of danicopan (ACH-0144471) in patients with paroxysmal nocturnal haemoglobinuria who have an inadequate response to eculizumab monotherapy
    Kulasekararaj, A.
    Risitano, A.
    Maciejewski, J.
    Notaro, R.
    Browett, P.
    Lee, J. W.
    Huang, M.
    Geffner, M.
    Brodsky, R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 13 - 14
  • [2] Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
    Kulasekararaj, Austin G.
    Risitano, Antonio M.
    Maciejewski, Jaroslaw P.
    Notaro, Rosario
    Browett, Peter
    Lee, Jong Wook
    Huang, Mingjun
    Geffner, Michael
    Brodsky, Robert A.
    BLOOD, 2021, 138 (20) : 1928 - 1938
  • [3] A PHASE 2 OPEN-LABEL PROOF OF CONCEPT STUDY OF THE ORAL, SMALL MOLECULE FACTOR D INHIBITOR, ACH-4471, IN UNTREATED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
    Risitano, A.
    Kulasekararaj, A.
    Lee, J. W.
    Notaro, R.
    Brodsky, R. A.
    Huang, M.
    Geffner, M.
    Browett, P.
    HAEMATOLOGICA, 2019, 104 : 4 - 4
  • [4] A phase 2, open-label study evaluating the safety and efficacy of combination pozelimab and cemdisiran therapy in patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab
    Kelly, Richard J.
    Houghton, Nicola
    Munir, Talha
    Muus, Petra
    Youngs, Nora
    Aurand, Lisa
    Senk, Brian
    Pavani, Rodrigo
    Perlee, Lorah
    Souttou, Amal
    Griffin, Morag
    IMMUNOBIOLOGY, 2023, 228 (05) : 6 - 6
  • [5] A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of Combination Pozelimab and Cemdisiran Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Switch from Eculizumab
    Kelly, Richard
    Houghton, Nicola
    Munir, Talha
    Muus, Petra
    Youngs, Nora
    Aurand, Lisa
    Dain, Bradley
    Pavani, Rodrigo
    Perlee, Lorah
    Souttou, Amal
    Griffin, Morag
    BLOOD, 2022, 140 : 8174 - 8175
  • [6] RESPONSE TO ECULIZUMAB COMBINED WITH CYCLOSPORINE AFTER FAILURE OF ECULIZUMAB MONOTHERAPY IN 2 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Deldicque, M.
    Knoops, L.
    Van den Neste, E.
    Delannoy, A.
    HAEMATOLOGICA, 2013, 98 : 585 - 586
  • [7] Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
    Jang, Jun Ho
    Wong, Lily
    Ko, Bor-Sheng
    Yoon, Sung-Soo
    Li, Katie
    Baltcheva, Irina
    Nidamarthy, Prasanna Kumar
    Chawla, Raghav
    Junge, Guido
    Yap, Eng Soo
    BLOOD ADVANCES, 2022, 6 (15) : 4450 - 4460
  • [8] Safety and efficacy of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH): Shepherd phase III clinical study results
    Risitano, A. M.
    Hillmen, P.
    Young, N. S.
    Schrezenmeier, H.
    Schubert, J.
    Urbano-Ispizua, A.
    Coyle, L.
    de Castro, C.
    Fu, C. L.
    Maciejewski, J. P.
    Di Bona, E.
    Antonioli, E.
    Gianfaldoni, G.
    Milano, F.
    Amendola, A.
    Kroon, H. A.
    Rother, R. P.
    Zanella, A.
    Rodeghiero, F.
    Iori, A. P.
    Luzzatto, L.
    Rotoli, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 88 - 88
  • [9] The efficacy and safety of eculizumab biosimilar in patients with paroxysmal nocturnal hemoglobinuria. Results of a phase III randomized open-label comparative clinical trial
    Kulagin, Aleksandr D.
    Bakirov, Bulat A.
    Davydkin, Igor L.
    Elykomov, Ilya, V
    Konstantinova, Tatiana S.
    Korobkin, Aleksandr, V
    Kosinova, Marina, V
    Mazurov, Vadim, I
    Minaeva, Natalia, V
    Proidakov, Andrei, V
    Ptushkin, Vadim V.
    Shatokhin, Yuri, V
    Lin'kova, Yulia N.
    Zinkina-Orikhan, Arina, V
    Morozova, Maria A.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (11) : 1340 - 1348
  • [10] Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study
    Zhang, Fengkui
    Han, Bing
    Zhang, Li
    Zhao, Xin
    BLOOD, 2024, 144 : 2689 - 2689
12345